Pharmacy Usual Items - NAFTA

NAFTA

Highlights

Revenue in the Pharmacy Usual Items market is projected to reach US$14.22bn in 2024.
Revenue is expected to show an annual growth rate (CAGR 2024-2029) of 5.20%, resulting in a market volume of US$18.32bn by 2029.
In global comparison, most revenue will be generated China (US$48.05bn in 2024).
In relation to total population figures, per person revenues of US$27.86 are generated in 2024.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Pharmacy Usual Items market in NAFTA is experiencing significant growth and development.

Customer preferences: Customers in the NAFTA region have shown a strong preference for convenience and accessibility when it comes to purchasing pharmacy usual items. With the rise of e-commerce and online shopping, consumers are increasingly turning to online platforms to purchase their usual items such as over-the-counter medications, personal care products, and vitamins. This shift in consumer behavior is driven by the convenience of being able to shop from the comfort of their own homes and the ability to compare prices and product reviews easily.

Trends in the market: One of the major trends in the Pharmacy Usual Items market in NAFTA is the increasing demand for natural and organic products. Consumers are becoming more health-conscious and are seeking products that are free from harmful chemicals and additives. This trend is driven by a growing awareness of the potential risks associated with certain ingredients and a desire for more sustainable and eco-friendly options. As a result, there has been a surge in the availability and variety of natural and organic pharmacy usual items in the market. Another trend in the market is the rising popularity of private label brands. Private label brands, also known as store brands or own brands, are products that are manufactured by retailers and sold under their own brand name. These brands offer consumers a more affordable alternative to national brands, while still maintaining a high level of quality. The increasing presence of private label brands in the Pharmacy Usual Items market in NAFTA is driven by cost-conscious consumers who are looking for value for money without compromising on product quality.

Local special circumstances: Each country within the NAFTA region has its own unique set of circumstances that are influencing the development of the Pharmacy Usual Items market. In the United States, for example, the market is highly competitive with a large number of players, both traditional brick-and-mortar retailers and online platforms. This intense competition has led to a focus on innovation and differentiation, with retailers offering a wide range of products and services to attract and retain customers. In Canada, the Pharmacy Usual Items market is heavily regulated, with strict rules and regulations governing the sale and distribution of pharmaceutical products. This regulatory environment has created barriers to entry for new players and has led to a consolidation of the market, with larger players dominating the industry.

Underlying macroeconomic factors: The growth and development of the Pharmacy Usual Items market in NAFTA are also influenced by underlying macroeconomic factors. Factors such as population growth, disposable income levels, and healthcare expenditure play a significant role in shaping consumer behavior and demand for pharmacy usual items. As the population in the NAFTA region continues to grow and disposable income levels rise, there is a greater demand for healthcare products and services, including pharmacy usual items. Additionally, the increasing focus on healthcare and wellness in the region is driving the demand for pharmacy usual items. Consumers are becoming more proactive in taking care of their health and are seeking out products that can help them prevent illness and maintain a healthy lifestyle. This trend is expected to continue driving the growth of the Pharmacy Usual Items market in NAFTA in the coming years.

Data coverage:

The data encompasses B2C enterprises. Figures are based on offline and online spending by consumers, including VAT. Not included are B2B and B2G sales, or other pharmaceutical sales through hospitals or retail stores such as supermarkets.

Modeling approach:

Market sizes are determined through a bottom-up approach, building on specific predefined factors for each market market. As a basis for evaluating markets, we use industry associations, third-party studies and reports and survey results from our primary research (e.g., the Statista Global Consumer Survey). In addition, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per country, consumer healthcare spending, GDP and internet penetration. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the relevant market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. For forecasting digital trends such as the online-pharmacy sales share we use exponential trend smoothing and the s-curve method. The main drivers are healthcare expenditure per country and consumer healthcare spending.

Additional notes:

The data is modeled using current exchange rates. The impact of the COVID-19 pandemic and the Russia-Ukraine war are considered at a country-specific level. The market is updated twice a year. GCS data is reweighted for representativeness.